Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer

陈军; 尚小云; 唐波; 钱锋; 石彦; 余佩武

您当前的位置：

首页 >

文章列表页 >

Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer

更新时间：2026-01-09

- Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer
- Journal of Army Medical University Vol. 31, Issue 10, Pages: 984-986(2009)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： {R392.13};R730.23;R735
- Published：2009
- 稿件说明：
移动端阅览
陈军,尚小云,唐波,钱锋,石彦,余佩武.胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J].陆军军医大学学报(原第三军医大学学报),2009,31(10):984-986.

　CHEN Jun,SHANG Xiao-yun,TANG Bo,QIAN Feng,SHI Yan,YU Pei-wu.Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(10):984-986.
陈军,尚小云,唐波,钱锋,石彦,余佩武.胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究[J].陆军军医大学学报(原第三军医大学学报),2009,31(10):984-986. DOI：

　CHEN Jun,SHANG Xiao-yun,TANG Bo,QIAN Feng,SHI Yan,YU Pei-wu.Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(10):984-986. DOI：

摘要

目的分析胃癌、食管癌中NY-ESO-1抗原基因的表达分布、NY-ESO-1

157-165

表位引发的特异性细胞免疫应答的状态与生存率的关系。方法利用RT-PCR方法检测112例胃癌和76例食管癌患者肿瘤标本和正常胃黏膜中NY-ESO-1抗原基因的表达，应用多色流式分析结合HLA-A2限制性表位肽/五聚体复合物技术对胃癌、食管癌患者外周血NY-ESO-1

157-165

表位特异性CTL进行精确定量。回顾分析20例NY-ESO-1

/HLA-A2

患者，随访3年，比较不同免疫应答状态对生存率的影响。结果食管癌患者中NY-ESO-1 mRNA表达频率（36.8%）明显高于胃癌（13.4%）。在20例检测到的NY-ESO-1

HLA-A2

患者中，强反应者（CD8

pentamer

cells ≥0.5%）生存率明显高于弱反应者（CD8

pentamer

cells＜0.5%）（P＜0.01）。结论胃癌、食管癌患者均有不同程度表达NY-ESO-1，其特异性免疫应答被检测到，并与生存率有关。

Abstract

Objective To analyze the relationship between the CTL response of NY-ESO-1 in gastric and esophageal cancer and survival rate in Chinese in order to provide data to develop a vaccine against the NY-ESO-1 positive cancer. Methods One hundred and twelve gastric cancer specimens and seventy-six esophageal cancer specimens were analyzed for the expression of NY-ESO-1 mRNA by RT-PCR. Pentamer staining were performed to analyze the frequency of NY-ESO-1

157-165

specific CTL in

NY-ESO-1/HLA-A2 positive patients. The correlation of CTL response and survival rate were analyzed. Results About 13.4% of the gastric cancer and 36.8% of the esophageal cancer were NY-ESO-1 positive. There were 23 patients with NY-ESO-1/HLA-A2 double positive. Frequency of Pentamer staining analysis and survival rate of these NY-ESO-1/HLA-A2 double positive patients indicated that high survival rate correlate with strong cellular immune response. Conclusion NY-ESO-1 expression is found in some of gastric and esophageal cancer

and NY-ESO-1

157-165

peptide can be regarded as a candidate for vaccination due to their expression and CTL response.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Oxaliplatin suppresses gastric cancer by inducing cuproptosis

Effects of LncRNA FGD5-AS1 on migration and invasion of gastric cancer cells by regulating miR-302b-3p/E2F1 axis

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Intelligent segmentation and staging system for esophageal cancer based on DAEUnet and ConvNeXt networks

Diagnostic value of endoscopic LCPL sign for high-risk intestinal metaplasia in gastric mucosa

Related Author

RAO Hang

YANG Hong

XIONG Mengyuan

ZHANG Liyong

HAN Xiao

DENG Boshao

WANG Lulu

CHEN Jian

Related Institution

Department of Immunology, College of Basic Medical Sciences， Army Medical University （Third Military Medical University）

Department of General Surgery， First Affiliated Hospital（Southwest Hospital）, College of Basic Medical Sciences， Army Medical University （Third Military Medical University）

Endoscopy Center, Qingdao Central Hospital of Rehabilitation University

Department of Gastroenterology, Qingdao Central Hospital of Rehabilitation University

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

⁰